Navigation Links
Oncologists Call For Medicare to Reconsider Anemia Drug Restrictions
Date:11/9/2007

WASHINGTON, Nov. 9 /PRNewswire-USNewswire/ -- The Community Oncology Alliance (COA), representing community cancer centers nationwide, formally requested that the Centers for Medicare & Medicaid Services (CMS) reconsider its decision to restrict the access of senior cancer patients to vital anemia-fighting drugs. Effective July 30, 2007, CMS implemented a National Coverage Determination (NCD) limiting oncologists' use of anemia-fighting drugs, referred to as Erythopoiesis Stimulating Agents (ESAs) in Medicare cancer patients undergoing chemotherapy treatment. Anemia is a common side effect of chemotherapy, and ESAs are used to minimize the need for red blood cell transfusions.

According to Dr. Patrick Cobb, a practicing oncologist from Billings, Montana, and Chairman of the COA Clinical Practices Committee, "What prompted this recent request to CMS to reconsider its decision to restrict ESA use was the release on November 8, 2007 of revised FDA-approved labeling for ESAs." Dr. Cobb added, "Unfortunately, what FDA considers safe and effective ESA use, CMS does not. As a result, our Medicare patients are not receiving the same standard of care as our younger patients."

The ESA labeling revisions include additional warnings related to risks associated with the use of ESAs "when dosed to target a hemoglobin of >= 12 g/dL" and instructs physicians to "use the lowest dose needed to avoid red blood cell transfusions" in order to minimize risk. However, the FDA specifically notes in both the revised label and its accompanying press release dated November 8, 2007 that, "no clinical data is available" to establish the risk of using ESAs when hemoglobin levels are less than 12 g/dL. The CMS NCD, on the other hand, arbitrarily prohibits ESA use when hemoglobin levels are 10 g/dL or higher.

"We use ESAs to reduce the need to give our patients transfusions, so we don't expose them to undue risks," said Dr. Cobb. "ESAs are important drugs, as are all the therapies we use to treat our patients--patient safety is always our primary concern. However, what CMS has done is to actually limit our ability to use ESAs in a way that minimizes transfusions."

In its reconsideration letter to CMS, COA notes, "It is readily apparent the CMS NCD essentially overrules the FDA scientific expertise by deeming ESAs unsafe and ineffective when used in the range of >=10 g/dL and <12 g/dL. Equally distressing is the fact that CMS is using a reimbursement policy to substitute its own clinical judgment, rather than allowing physicians to exercise their own clinical judgment for each individual patient's circumstances, as recommended in the newly revised FDA-approved label." COA further notes, "there is evidence to suggest that initiating ESA treatment at a hemoglobin level >10 g/dL significantly reduces the risk of transfusion."

COA is asking CMS for immediate reconsideration of the portions of the NCD dealing with cancer patients undergoing chemotherapy.

For additional information contact Ted Okon, COA Executive Director, taokon@sosacorn.com, 203-715-0300.

The Community Oncology Alliance (COA) is a non-profit organization. The mission of COA is to foster and protect the community oncology delivery system in the United States through public policy, advocacy, and education. Eighty-four percent of Americans battling cancer receive high quality, affordable, and accessible cancer care in community oncology clinics close to home. The accessibility of high quality cancer care, coupled with earlier diagnosis and new therapies, has resulted in a decreased cancer mortality rate.


'/>"/>
SOURCE Community Oncology Alliance
Copyright©2007 PR Newswire.
All rights reserved

Related medicine technology :

1. Local Medicare Contractors Expand Hypertension Coverage for CardioDynamics BioZ(R) ICG Technology
2. Medicare Contractor Establishes Reimbursement Coding Guidance for Monograms Trofile Assay
3. Biopure Seeks Compassionate Use Protocol for Treatment of Acute Anemia
4. ASCO and ASH Release Updated Guideline on the Use of Chemotherapy-Related Anemia Treatments in Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... Oct. 11, 2017  True Health, a leader ... its effort during National Breast Cancer Awareness month ... risks. Research ... calculated that more than 10 million American women ... in BRCA1 or BRCA2 and have not had testing. ...
(Date:10/5/2017)... 2017  In response to the nationwide opioid ... Surgeons (AAOMS) released prescribing recommendations that urge ibuprofen ... as a first-line therapy to manage a patient,s ... Recognizing the value and importance of ... Prescribing: Acute and Postoperative Pain Management" stresses that ...
(Date:10/2/2017)... 2017  Eli Lilly and Company (NYSE: ... third quarter of 2017 on Tuesday, October 24, 2017. ... day with the investment community and media to further ... call will begin at 9 a.m. Eastern time. Investors, ... webcast of the conference call through a link that ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... October 13, 2017 , ... ... Software Development, has been awarded a contract by the Center for Medicare and ... aims to accelerate the enterprise use of Agile methodologies in a consistent and ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... for healthcare compliance program management, will showcase a range of technology and learning ... Assisted Living (NCAL) Convention and Expo to be held October 14–18, 2017 at ...
(Date:10/12/2017)... ... October 12, 2017 , ... The company ... of today’s consumer and regulatory authorities worldwide. From Children’s to Adults 50+, every ... meet the highest standard. , These products are also: Gluten Free, Non-GMO, ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... leader in post-acute health care, have expanded their existing home health joint venture ... , AccentCare has been operating a joint venture home health company with Asante, ...
(Date:10/12/2017)... Malvern, PA (PRWEB) , ... October 12, 2017 , ... ... is the recipient of a 2017 Folio Magazine Eddie Digital Award for ‘Best ... New York City on October 11, 2017. , The annual award competition recognizes editorial ...
Breaking Medicine News(10 mins):